QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:OCX

OncoCyte (OCX) Stock Forecast, Price & News

$3.22
-0.02 (-0.62%)
(As of 09/21/2023 ET)
Compare
Today's Range
$3.10
▼
$3.26
50-Day Range
$3.19
▼
$4.13
52-Week Range
$3.10
▼
$16.94
Volume
25,217 shs
Average Volume
19,503 shs
Market Capitalization
$26.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.31
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

OncoCyte MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
127.1% Upside
$7.31 Price Target
Short Interest
Bearish
2.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.49mentions of OncoCyte in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.09) to ($3.57) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

881st out of 961 stocks

Diagnostic Substances Industry

11th out of 12 stocks

See Top Rated MarketRank™ Stocks Here

OCX stock logo

About OncoCyte (NASDAQ:OCX) Stock

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OCX Price History

OCX Stock News Headlines

September 21, 2023 | americanbankingnews.com
OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com
September 18, 2023 | finanznachrichten.de
Oncocyte Corporation: Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
September 21, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
September 18, 2023 | finance.yahoo.com
Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
September 15, 2023 | americanbankingnews.com
OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com
September 6, 2023 | finance.yahoo.com
Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023 | finanznachrichten.de
Oncocyte Corporation: Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage
August 28, 2023 | finance.yahoo.com
Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage
September 21, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
August 24, 2023 | nasdaq.com
Benchmark Maintains Oncocyte (OCX) Speculative Buy Recommendation
August 15, 2023 | msn.com
Piper Sandler Maintains Oncocyte (OCX) Neutral Recommendation
August 11, 2023 | msn.com
Needham Maintains Oncocyte (OCX) Buy Recommendation
August 10, 2023 | finanznachrichten.de
Oncocyte Corporation: Oncocyte Reports Second Quarter 2023 Financial Results
August 10, 2023 | finance.yahoo.com
Oncocyte Reports Second Quarter 2023 Financial Results
August 9, 2023 | finance.yahoo.com
Oncocyte Regains Compliance With Nasdaq Listing Requirements
August 9, 2023 | finanznachrichten.de
Oncocyte Corporation: Oncocyte Regains Compliance With Nasdaq Listing Requirements
August 8, 2023 | finance.yahoo.com
Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference
August 3, 2023 | finance.yahoo.com
Oncocyte To Announce Second Quarter 2023 Financial Results
August 2, 2023 | msn.com
Oncocyte (OCX) Price Target Increased by 1900.00% to 7.14
July 25, 2023 | finance.yahoo.com
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
July 25, 2023 | finanznachrichten.de
Oncocyte Corporation: Oncocyte Announces 1-For-20 Reverse Stock Split
July 24, 2023 | finance.yahoo.com
Oncocyte Announces 1-For-20 Reverse Stock Split
July 14, 2023 | finance.yahoo.com
OCX - OncoCyte Corporation
June 27, 2023 | finanznachrichten.de
Oncocyte Corporation: Oncocyte Begins Manufacturing Transplant Blood Test
June 27, 2023 | finance.yahoo.com
Oncocyte Begins Manufacturing Transplant Blood Test
June 1, 2023 | finance.yahoo.com
Oncocyte Corporation to Present at the LD Micro Invitational XIII
May 11, 2023 | finanznachrichten.de
Oncocyte Corporation: Oncocyte Reports First Quarter 2023 Financial Results
See More Headlines
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Company Calendar

Last Earnings
8/10/2023
Today
9/21/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCX
CUSIP
N/A
CIK
1642380
Web
oncocyte.com
Phone
(949) 409-7600
Fax
510-521-3389
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.31
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$4.25
Forecasted Upside/Downside
+127.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-72,900,000.00
Net Margins
N/A
Pretax Margin
-1,472.21%
Return on Equity
-55.56%
Return on Assets
-25.03%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.74
Quick Ratio
2.74

Sales & Book Value

Annual Sales
$1.10 million
Price / Sales
24.10
Cash Flow
$0.87 per share
Price / Cash Flow
3.69
Book Value
$5.78 per share
Price / Book
0.56

Miscellaneous

Outstanding Shares
8,241,000
Free Float
8,081,000
Market Cap
$26.54 million
Optionable
Optionable
Beta
1.58
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Joshua Riggs (Age 40)
    Pres, CEO & Director
    Comp: $373.2k
  • Mr. James Liu (Age 27)
    Sr. Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer
    Comp: $192.48k
  • Mr. Yuh-Min Chiang Ph.D.
    Chief Technology Officer
  • Dr. Ekkehard Schutz M.D.
    Ph.D., Chief Science Officer
  • Ms. Sandra O'Donald
    Sr. VP of Bus. Operations
  • Dr. Michael D. West Ph.D. (Age 70)
    Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.
  • Peter Hong
    Sec.
  • Ms. Sara Riordan
    Director of Medical Education

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













OCX Stock - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OCX shares.
View OCX analyst ratings or view top-rated stocks.

What is OncoCyte's stock price forecast for 2023?

4 brokerages have issued 1 year price targets for OncoCyte's stock. Their OCX share price forecasts range from $4.25 to $10.00. On average, they anticipate the company's stock price to reach $7.31 in the next year. This suggests a possible upside of 127.1% from the stock's current price.
View analysts price targets for OCX or view top-rated stocks among Wall Street analysts.

How have OCX shares performed in 2023?

OncoCyte's stock was trading at $6.4180 on January 1st, 2023. Since then, OCX shares have decreased by 49.8% and is now trading at $3.22.
View the best growth stocks for 2023 here.

When is OncoCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our OCX earnings forecast.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) announced its earnings results on Thursday, August, 10th. The company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($2.60) by $1.53. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.60 million.

When did OncoCyte's stock split?

OncoCyte's stock reverse split before market open on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN).

What is OncoCyte's stock symbol?

OncoCyte trades on the NASDAQ under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by many different retail and institutional investors. Top institutional shareholders include AWM Investment Company Inc. (172.16%), Pura Vida Investments LLC (165.35%), Geode Capital Management LLC (14.91%), BlackRock Inc. (14.71%), Renaissance Technologies LLC (1.68%) and LPL Financial LLC (1.55%). Insiders that own company stock include Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends.

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $3.22.

How much money does OncoCyte make?

OncoCyte (NASDAQ:OCX) has a market capitalization of $26.54 million and generates $1.10 million in revenue each year.

How can I contact OncoCyte?

OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.

This page (NASDAQ:OCX) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -